Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
October 26 2022 - 1:46PM
Business Wire
- Highlighting latest clinical findings, including comparative
efficacy for ocular itch relief between Pataday Once Daily Relief
Extra Strength and an oral antihistamine
- Forthcoming innovations in eye care to be previewed,
including TOTAL30 for Astigmatism
- TOTAL portfolio to be presented at an engaging event in
partnership with FORTUNE Brand Studios, featuring the star of
“Shark Tank” and CEO of Cyderes Robert Herjavec
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will feature a host of
innovations across its broad portfolio of products along with
pertinent practice takeaways at the American Academy of Optometry
Annual Meeting (#Academy22) in San Diego, California, on October
27, 2022. The meeting coincides with Alcon’s Diamond Jubilee,
celebrating 75 years of helping people see brilliantly. Alcon will
host an engaging on-site program featuring events and the latest
clinical presentations across contact lenses, allergy, dry eye and
more.
“For 75 years, Alcon has remained steadfast in its mission to
connect industry-leading vision care innovations for all eye care
needs and professionals who are helping patients across the world,”
said Sean Clark, General Manager, U.S. Vision Care. “We are
thrilled to continue this work as industry leaders by presenting an
array of exciting events and presentations at Academy, including
showcasing the growth of Alcon over the past 75 years and
groundbreaking plans for the future.”
Clinical Data and Research Findings in
Contact Lenses and Ocular Allergies
Several research- and investigator-initiated trials supported by
Alcon will be presented at the event highlighting the results of
clinical research around the efficacy and performance of Pataday®,
PRECISION1® contact lenses, and some including competitive
products. One notable study shows that a single dose of Pataday
Once Daily Relief Extra Strength was significantly more efficacious
than a single dose of Claritin^ Tablets 24-Hour in reducing ocular
itching in subjects with allergic conjunctivitis at both 15-minute
onset of action and 24-hour duration of action evaluations.
- Thursday, October 27
- Poster Presentation: A Comparison of the Onset of Action and
Duration of Action of Pataday® Once Daily Relief Extra Strength to
Claritin Tablets 24-Hour in Reducing Ocular Itching in Subjects
with Allergic Conjunctivitis. Presented by Jason Chin, OD, &
Kara Quealy, MS (available for questions in Exhibit Hall H from
4:30-6:30 p.m. PST)
- Friday, October 28
- Poster Presentation: Performance of Verofilcon A Daily
Disposable Contact Lenses in Digital Device Users. Presented by
Marc-Matthias Schulze, PhD, Dipl. Ing., et al (available for
questions in Exhibit Hall H from 1:00-3:00 p.m. PST)
- Poster Presentation: Clinical Performance of Two Daily
Disposable Toric Soft Contact Lenses – Verofilcon A Versus
Etafilcon A. Presented by Mark Perry, OD, et al (available for
questions in Exhibit Hall H from 1:00-3:00 p.m. PST)
- Poster Presentation: Clinical Performance Comparison of Two
Commercially Available Daily Disposable Soft Contact Lenses:
Verofilcon A Versus Somofilcon A. Presented by Katherine Bickle,
OD, PhD, et al (available for questions in Exhibit Hall H from
1:00-3:00 p.m. PST)
Innovations in Eye Care Expand Reach of
Alcon Product Offerings
To continue its efforts in the advancement of eye care, Alcon
will be expanding its footprint in the vision care market with the
announcement of upcoming product launches and expansions,
including:
- TOTAL30® for Astigmatism, the much-anticipated toric lens born
from the trusted Water Gradient lens technology of TOTAL30® sphere
lenses, the first and only monthly replacement Water Gradient
contact lens.1
- Following its launch in 2020 and during COVID-19, Alcon
accelerated MARLO access to help Eye Care Professionals (ECPs)
better connect with their patients and continues to impact the eye
care industry with its cutting-edge digital platform. In June 2022,
the company announced MARLO had achieved the milestone of more than
one million patients enrolled. In 2023, Alcon will expand its MARLO
services to provide patients with greater access to eye care.
TOTAL Portfolio x FORTUNE Brand Studios
to Provide Resources for ECPs to Optimize Practice Success and
Patient Loyalty, Satisfaction
The Secrets to Success: Featuring Robert Herjavec and TOTAL® to
include Herjavec’s personal experience as a contact lens patient
and lessons learned from his career as an entrepreneur, CEO of
Cyderes, and his time on ABC’s “Shark Tank,” including how they can
apply to ECPs’ businesses. The 1-hour event will include a panel
discussion with leading optometrists, Drs. Pamela Lowe and Amanda
Nanasy, and Associate Consultant from leading healthcare consulting
firm, BSM, Barbra Dey. The event will take place at the Hilton San
Diego Bayfront, Room Indigo BF.
- Thursday, October 27 from 6:30 p.m. to 7:30 p.m. PST. Doors
will open at 6 p.m. and close at 8 p.m. for beverages and
networking.
- Fireside chat featuring business expert, star of “Shark Tank,”
and CEO of Cyderes, Robert Herjavec, and moderator and
international award-winning journalist Del Irani
- Panel discussion highlighting “your patients’ contact lens
comfort,” presented by Del Irani, Dr. Pamela Lowe, Dr. Amanda
Nanasy and Barbra Dey
- Closing remarks (opportunity for networking in the room from
7:30-8:00 p.m.)
Visit Alcon’s booth #601 for important information on Alcon’s
innovative products and programs featured in this release.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
^Claritin is not owned or affiliated with Alcon
References
- A02491-REP-198231-1 Outermost Surface Softness Analysis of
lehfilcon A Contact Lenses and Correlation with Water Content Based
upon Petrisoft Gels.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026005883/en/
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Sep 2023 to Sep 2024